Skip to main content
. 2022 Jul;11(7):1224–1239. doi: 10.21037/gs-22-330

Figure 3.

Figure 3

Nomogram for predicting 3- and 5-year BCSS among patients in the non-surgery group after PSM. IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; HR, hormone receptor; HER2, human epidermal growth factor receptor-2; TN, triple-negative (HRHER2); BCSS, breast cancer-specific survival; PSM, propensity score matching.